U.S. Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type (Crohn's Disease, Ulcerative Colitis), By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

U.S. IBD Treatment Market Size & Trends

The U.S. inflammatory bowel disease treatment market size was estimated at USD 13.12 billion in 2024 and is projected to grow at a CAGR of 2.7% from 2025 to 2030. The market is driven by the rising adoption of advanced therapeutic options such as biologics, JAK inhibitors, and personalized treatment strategies for managing Crohn’s disease and ulcerative colitis. Increasing awareness, introducing novel drug formulations, and supportive reimbursement frameworks are expected to contribute to market expansion over the forecast period.

The rising prevalence of Inflammatory Bowel Disease (IBD) in the United States is significantly driving market growth for IBD treatments. For instance, in November 2024, according to the Crohn's & Colitis Foundation, over 3 million Americans were living with IBD as of 2020, and this number has been steadily increasing, with more than 100,000 American youth under 20 affected, highlighting a growing pediatric patient pool as well. A recent study published in 2023 indicated that the incidence of IBD is rising, particularly among younger populations, intensifying the demand for advanced and early intervention therapies.

The U.S. market has experienced substantial progress in biologic therapies, offering improved treatment options for patients with inflammatory bowel disease (IBD). For instance, in June 2022, the FDA approved Risankizumab (Skyrizi), a monoclonal antibody designed for moderate-to-severe Crohn's disease, representing a major advancement in targeted therapy. Skyrizi joins a growing class of biologics that works by interrupting specific immune pathways to reduce intestinal inflammation. Other widely adopted biologics include Vedolizumab (Entyvio) and Ustekinumab (Stelara), which have demonstrated strong efficacy and favorable safety profiles. Their ability to achieve remission with fewer systemic side effects has positioned them as preferred options in clinical practice. As a result, the adoption of biologics continues to rise, transforming IBD management across the country.

Future developments in the U.S. IBD market are expected to emphasize personalized and preventive care. Microbiome-based therapies are gaining attention for their potential to rebalance gut flora and reduce inflammation. Research into gene therapies and stem cell approaches may offer long-term disease control or potential cures. Digital platforms for remote monitoring and real-time symptom tracking will likely expand.

U.S. Inflammatory Bowel Disease Treatment Pipeline Analysis

Market Concentration & Characteristics

The U.S. Inflammatory Bowel Disease (IBD) treatment market is marked by a high degree of innovation, with leading players like Biogen, Novartis AG, Eli Lilly and Company, and Johnson & Johnson Services, Inc. investing heavily in the development of next-generation biologics and small-molecule therapies. Advances include improved monoclonal antibodies with enhanced specificity and reduced immunogenicity, as well as the exploration of oral JAK inhibitors and S1P modulators to increase patient compliance.

The U.S. IBD treatment market poses substantial entry barriers, particularly for new or smaller biopharma companies. Developing biologics like monoclonal antibodies or biosimilars demands extensive R&D infrastructure, high capital investment, and regulatory expertise. CELLTRION INC, known for its biosimilar portfolio, faces regulatory and commercial challenges in establishing clinical equivalence and safety in a highly scrutinized market. Manufacturing consistency, especially for biologics, is critical, necessitating robust quality assurance systems.

The FDA and EMA enforce rigorous regulatory frameworks for IBD treatments, especially for biologics and novel small-molecule drugs. Regulatory expectations include comprehensive safety and efficacy data across Crohn’s Disease and Ulcerative Colitis populations, often requiring post-marketing surveillance and risk management plans. Eli Lilly and UCB S.A., both advancing innovative immunology therapies, must align clinical protocols with strict endpoints and trial designs to secure approval.

IBD therapies face substitution pressure from biosimilars and alternative mechanisms of action. For instance, CELLTRION INC. offers infliximab biosimilars as cost-effective options, potentially disrupting originator products. Oral agents, including JAK inhibitors and S1P receptor modulators, provide convenient alternatives to intravenous or subcutaneous biologics, especially for moderate to severe cases. However, these substitutes vary in safety profiles, with some posing risks such as thromboembolism or immunosuppression. Treatment decisions are increasingly guided by therapeutic response monitoring and patient lifestyle considerations, shifting the market toward a more personalized approach.

Companies like Novartis AG and UCB S.A. are strategically expanding their IBD portfolios beyond the U.S., targeting high-growth regions such as Asia-Pacific and Latin America, where IBD incidence is rising due to urbanization and dietary changes. Leveraging partnerships for localized production and regulatory navigation, these companies aim to reduce treatment costs and improve access. In the U.S., distribution channels are evolving, with a shift toward specialty pharmacies and integrated delivery networks that streamline biologics administration and follow-up. Digital health tools and remote monitoring are also enhancing patient engagement and adherence.

Type Insights

Crohn's disease segment held the largest market share driven by the growing demand for advanced treatment options and the availability of therapies such as biologics and JAK inhibitors. The increasing prevalence of Crohn's disease and ongoing research into more effective therapies are expected to sustain the segment's dominant position throughout the forecast period.

On the other hand, the ulcerative colitis segment is anticipated to register the fastest CAGR of 3.5% over the forecast period. This can be attributed to the increasing adoption of biologics and targeted therapies to treat ulcerative colitis. The rising prevalence of the disease and advancements in treatment options are expected to drive the segment's growth further.

Drug Class Insights

The TNF inhibitors segment held the largest market share of 62.0% in 2024. This can be attributed to the well-established efficacy of TNF inhibitors in treating IBD, particularly in managing inflammation and inducing disease remission. The segment benefits from a strong clinical foundation and continued advancements in the formulation and delivery of these drugs. In addition, the widespread use of TNF inhibitors in both Crohn's disease and ulcerative colitis contributes significantly to their dominant market position.

The JAK inhibitors segment is projected to grow at a significant CAGR over the forecast period. JAK inhibitors have emerged as a key therapeutic option in the treatment landscape for inflammatory bowel disease (IBD), especially for patients with moderate to severe ulcerative colitis and Crohn’s disease. These orally administered small molecules target Janus kinase (JAK) pathways, which mediate the activity of various pro-inflammatory cytokines central to the immune response in IBD. By modulating these pathways, JAK inhibitors reduce systemic and localized inflammation, helping achieve and maintain disease remission. Their oral administration offers an advantage in patient convenience compared to biologic injectable, especially for those with inadequate response to conventional therapies.

Route Of Administration Insights

The injectable segment dominated the market with a 92.00% share in 2024. This can be attributed to the widespread use of biologics and biosimilars, which offer effective treatment for IBD such as Crohn's disease and ulcerative colitis. The injectable route provides systemic treatment, allowing the medication to circulate throughout the body and directly target inflamed areas.

The oral segment is projected to grow at the fastest CAGR over the forecast period, driven by the increasing preference for convenient, non-invasive treatment options. Oral therapies, such as JAK inhibitors, are gaining popularity due to their ease of use, reducing the need for injections and improving patient adherence to treatment regimens.

Distribution Channel Insights

The hospital pharmacies segment held the largest revenue share of 46.65% in 2024 due to their significant role in the administration of specialized treatments for IBD, such as Crohn’s disease and ulcerative colitis. Hospital pharmacies are integral in managing complex medication regimens and providing tailored care for IBD patients.

The online pharmacy segment is expected to register the fastest CAGR over the forecast period. This growth can be attributed to the increasing adoption of digital platforms, the convenience they offer patients to access treatments, and the growing trend of home delivery services for medications, especially for chronic conditions like IBD.

Regional Insights

West U.S. Inflammatory Bowel Disease Treatment Market Trends

The Western U.S. remains a key region in IBD treatment innovation, driven by the presence of major biotechnology hubs and academic research centers in California and Washington. Companies like Gilead Sciences, Genentech (a member of the Roche Group), and Biogen leverage these ecosystems to conduct cutting-edge clinical trials and accelerate new product development.

Midwest U.S. Inflammatory Bowel Disease Treatment Market Trends

The Midwest U.S. showcases a stable and growing IBD treatment landscape supported by strong healthcare systems and academic partnerships in states like Illinois, Minnesota, and Ohio. Companies such as Johnson & Johnson (Stelara, Remicade) and CELLTRION INC actively participate in real-world studies and biosimilar introduction.

Northeast U.S. Inflammatory Bowel Disease Treatment Market Trends

The Northeast, home to renowned medical institutions and pharmaceutical giants like Merck & Co., Inc. and Eli Lilly, is at the forefront of adopting personalized IBD treatment strategies. Focus is high on targeted therapies, including IL inhibitors and JAK inhibitors, often used in combination to manage refractory Crohn’s Disease and Ulcerative Colitis.

Southwest U.S. Inflammatory Bowel Disease Treatment Market Trends

The Southwest U.S., including states like Texas and Arizona, is witnessing rising IBD prevalence due to demographic shifts and improved diagnostic rates. UCB S.A. and Novartis AG are expanding their market presence here through targeted outreach and payer collaborations.

Southeast U.S. Inflammatory Bowel Disease Treatment Market Trends

The Southeast U.S. is emerging as a significant market for IBD treatments, with increasing disease awareness, improved access to gastroenterologists, and expanding healthcare infrastructure. Biogen and CELLTRION INC are key players driving biosimilar penetration in this cost-sensitive market. While aminosalicylates and corticosteroids remain staples in initial treatment, biologics-especially TNF inhibitors and IL inhibitors-are being increasingly integrated into treatment protocols for patients with moderate-to-severe disease.

Key U.S. Inflammatory Bowel Disease Treatment Company Insights

Some of the key players in the Inflammatory Bowel Disease (IBD) treatment market include Biogen; Novartis AG; Eli Lilly and Company; UCB S.A.; CELLTRION INC.; Merck & Co., Inc.; and Johnson & Johnson Services, Inc. These companies focus on strategies such as mergers and acquisitions, collaborations, and developing new products to strengthen their market presence.

• Landos Biopharma: Landos Biopharma is advancing NX-13, a first-in-class oral small molecule targeting the NLRX1 pathway to modulate the immune response in inflammatory bowel disease. Designed for enhanced safety and tolerability, NX-13 has shown favorable biomarker modulation and clinical signals in early-phase trials for ulcerative colitis. The company’s novel approach offers a differentiated mechanism from existing biologics, positioning NX-13 as a potential maintenance therapy with fewer immunosuppressive risks.

• MorphoSys AG: MorphoSys, through its partnership with Incyte, is developing guselkumab, an IL-23 inhibitor, for Crohn’s Disease and Ulcerative Colitis. Although originally developed for psoriasis, IL-23 inhibitors are now being repositioned in IBD with promising efficacy and improved dosing convenience. Guselkumab's Phase II/III IBD trials aim to validate its utility in biologic-experienced patient populations.

• Precision IBD (a Takeda-backed company): Precision IBD is working on leveraging AI-driven diagnostics and targeted therapies to personalize treatment for IBD patients. Their investigational platforms aim to identify molecular subtypes of IBD to guide therapy selection, especially in patients with treatment-resistant Crohn’s Disease or Ulcerative Colitis. This precision medicine approach could revolutionize IBD management by reducing trial-and-error prescribing and improving long-term outcomes.

Recent Developments

• In April 2024, Celltrion Inc. USA expanded access to ZYMFENTRA (infliximab-dyyb) in the U.S. through a collaboration with Cigna Healthcare and Express Scripts, making the subcutaneous infliximab available to over 16 million insured lives. This partnership enhances patient access to an innovative and convenient treatment option for moderate to severe ulcerative colitis and Crohn’s disease, focusing on patient safety and monitoring protocols.

• In March 2025, Johnson & Johnson Services, Inc. received U.S. FDA approval for TREMFYA (guselkumab), the first and foremost IL-23 inhibitor with subcutaneous and intravenous induction options, for treating adults with moderately to severely active Crohn’s disease (CD). This approval expands treatment options for nearly three million Americans living with IBD.

• In March 2025, Johnson & Johnson Services, Inc. launched a newly FDA-approved dual-acting monoclonal antibody therapy for moderate to severe ulcerative colitis (UC) in the U.S. In clinical trials, this therapy demonstrated significant symptom improvement and intestinal healing, marking a major advancement in IBD treatment.

U.S. Inflammatory Bowel Disease Treatment Market Report Scope

U.S. Inflammatory Bowel Disease Treatment Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. inflammatory bowel disease treatment market report based on type, drug class, route of administration, distribution channel, and region:

• Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Crohn's Disease

  • Ulcerative Colitis

• Drug Class Outlook (Revenue, USD Million, 2018 - 2030)

  • Aminosalicylates

  • Corticosteroids

  • TNF inhibitors

  • IL inhibitors

  • Anti-integrin

  • JAK inhibitors

  • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacy

  • Retail Pharmacy

  • Online Pharmacy

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • West

  • Midwest

  • Northeast

  • Southwest

  • Southeast